These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 24329157)

  • 1. Approaches for high-throughput pharmacokinetic screening of low-molecular-weight drug candidates.
    Fontana S
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):139-42. PubMed ID: 24329157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of high-throughput ADME in drug discovery.
    Kassel DB
    Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in microfluidics for drug discovery.
    Lombardi D; Dittrich PS
    Expert Opin Drug Discov; 2010 Nov; 5(11):1081-94. PubMed ID: 22827746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving lead generation success through integrated methods: transcending 'drug discovery by numbers'.
    Campbell JB
    IDrugs; 2010 Dec; 13(12):874-9. PubMed ID: 21154146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing the challenges of low clearance in drug research.
    Di L; Obach RS
    AAPS J; 2015 Mar; 17(2):352-7. PubMed ID: 25567366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of chemical diversity.
    Triggle DJ
    Curr Protoc Pharmacol; 2001 May; Chapter 9():Unit 9.1. PubMed ID: 21971814
    [No Abstract]   [Full Text] [Related]  

  • 9. Case study: technology initiative led to advanced lead optimization screening processes at Bristol-Myers Squibb, 2004-2009.
    Zhang L; Cvijic ME; Lippy J; Myslik J; Brenner SL; Binnie A; Houston JG
    Drug Discov Today; 2012 Jul; 17(13-14):733-40. PubMed ID: 22425710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics.
    Roberts SA
    Xenobiotica; 2001; 31(8-9):557-89. PubMed ID: 11569526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Discovery Goes Three-Dimensional: Goodbye to Flat High-Throughput Screening?
    Eglen RM; Randle DH
    Assay Drug Dev Technol; 2015 Jun; 13(5):262-5. PubMed ID: 26121065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Label-free screening assays: a strategy for finding better drug candidates.
    Lunn CA
    Future Med Chem; 2010 Nov; 2(11):1703-16. PubMed ID: 21428840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo rat PK profiling in drug discovery: new challenges.
    Zonzini L; Bianchi F; Cesari N; Sartori M
    Expert Opin Drug Discov; 2010 Nov; 5(11):1031-7. PubMed ID: 22827743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescence-based high-throughput screening assay for drug interactions with UGT1A6.
    Soikkeli A; Kurkela M; Hirvonen J; Yliperttula M; Finel M
    Assay Drug Dev Technol; 2011 Oct; 9(5):496-502. PubMed ID: 21438674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current trends in epigenetic drug discovery.
    Stolfa DA; Einsle O; Sippl W; Jung M
    Future Med Chem; 2012 Oct; 4(16):2029-37. PubMed ID: 23157236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
    Bergsdorf C; Ottl J
    Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case.
    Kogej T; Blomberg N; Greasley PJ; Mundt S; Vainio MJ; Schamberger J; Schmidt G; Hüser J
    Drug Discov Today; 2013 Oct; 18(19-20):1014-24. PubMed ID: 23127858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent trends and observations in the design of high-quality screening collections.
    Renner S; Popov M; Schuffenhauer A; Roth HJ; Breitenstein W; Marzinzik A; Lewis I; Krastel P; Nigsch F; Jenkins J; Jacoby E
    Future Med Chem; 2011 Apr; 3(6):751-66. PubMed ID: 21554080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An integrated bioanalytical platform for supporting high-throughput serum protein binding screening.
    Zhang J; Shou WZ; Vath M; Kieltyka K; Maloney J; Elvebak L; Stewart J; Herbst J; Weller HN
    Rapid Commun Mass Spectrom; 2010 Dec; 24(24):3593-601. PubMed ID: 21080511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of discovery DMPK scientists in industry: where do we go from here?
    Moriwaki T
    Drug Metab Pharmacokinet; 2012; 27(2):169-70. PubMed ID: 22531680
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.